Due to the limitations of CDK4/6is in triple-negative breast cancer (TNBC), a CDK4/6i polyamino acid nanoparticle formulation, named NG2000/ABE, was developed; this formulation effectively enhanced the efficacy of abemaciclib by inducing ICD in vitro and in vivo [55,56]. The gene discussed is CDK4; the disease is triple-negative breast carcinoma.